NEW YORK, May 30 – RheoGene, a privately held gene expression company based in Charlottesville, Va., announced Wednesday that it had appointed several genomics industry heavyweights to its scientific advisory board.
Michael Ashburner, the joint head of the European Molecular Biology Laboratory and the European Bioinformatics Institute, and Leroy Hood, director of the Institute for Systems Biology, were both named to the board as was Jeffrey Trent, scientific director of the National Human Genome Research Institute.
Aaron Shatkin, director of the Center for Advanced Biotechnology and Medicince, will serve as chairman of the scientific advisory board.
"We are very pleased that these leading scientists have agreed to help guide research and discovery for RheoGene's products and technologies," Mohan Philip, RheoGene's chief scientific officer, said in a statement.
RheoGene has developed RheoSwitch, a gene expression technology that can turn gene expression on and off and allow it to be dialed up and down. The technology can be applied in proteomics, functional genomics, systems biology, and bioinformatics.